Medical device firm Lumenis has introduced new Pulse 100H and Pulse 50H laser systems, developed to treat benign prostatic hyperplasia (BPH) and stones.
The Lumenis Pulse 100H, claimed to be the next generation of the VersaPulse PowerSuite 100 Watt system, has been developed to treat a wide array of clinical urologic indications, including BPH, stones, tumors or strictures.
It will also be used in the treatment of other specialties such as general surgery, ENT, gynecology and pulmonary surgery.
The system allows users to carry out holmium laser enucleation of the prostate (HoLEP), the gold standard treatment for BPH and stone dusting.
Pulse 100H, which features dual pedals for improved ease of use and standby mode for minimizing cost per procedure, provides combination of laser parameters addressing around 70 types of procedures.
The firm has also introduced new Pulse 50H laser system, which holds capability to address any type or size of stone in lithotripsy.
The system is a comprehensive solution, which offers0.2J of energy per pulse to minimize migration of even the smallest stone and it can also be upgraded to the new Pulse 100H.
Lumenis CEO Tzipi Ozer-Armon said: "With our commitment to the Endourological Society, we are proud to present two new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic market need in the field of minimally invasive urological surgery.
"The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting and empower users to achieve more than 70 types of procedures in a range of clinical specialties."
The company is exhibiting the new laser systems at the 33rd World Congress of Endourology (WCE) in London, UK, which is being held from 1 to 4 October.
Image: The Lumenis Pulse 100H laser system. Photo: courtesy of Lumenis Ltd.